Proposal to widen access to febuxostat to treat gout
The Pharmaceutical Management Agency proposes funding febuxostat for people with gout who cannot adequately control symptoms with, or cannot tolerate, allopurinol.
- Closing date
- 30 September 2026
- Added to Civics
- 17 September 2026
- Source category
- Other public body
- Source body
- Pharmaceutical Management Agency
- Last checked
- 23 September 2026
Closes in 7 days
Plain-English summary
The Pharmaceutical Management Agency proposes funding febuxostat for people with gout who cannot adequately control symptoms with, or cannot tolerate, allopurinol.
Read the official consultation material for the detailed proposal, supporting documents and submission method.
Why it matters
People eligible for second-line treatment would have febuxostat or probenecid as options.
Around 5,500 people are estimated to benefit in the first year, increasing to 7,300 by year 5.
Who may care
- People with gout
- Family/whānau and friends of people who use medicines
- Health care professionals and consumer groups
How to make a submission
- Read the official consultation material.
- Submit feedback through the official consultation page before the closing date.
Disclaimer
Civics.nz is an independent plain-English guide and is not an official government website. Always check the official source before making a submission.